Impact of Inflammatory Bowel Disease (IBD) and IBD Medications on Risk of Hyperlipidemia and in vitro Hepatic Lipogenic-Related Gene Expression: A Population-Based Cohort Study
Patients with inflammatory bowel disease (IBD) present a higher risk of developing cardiovascular diseases (CVDs) due to chronic inflammation, which plays an essential role in atherogenesis. Hyperlipidemia is another risk factor for CVDs; however, the association between IBD, IBD medications, and hy...
Saved in:
| Published in | Frontiers in medicine Vol. 9; p. 910623 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Frontiers Media S.A
13.06.2022
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Patients with inflammatory bowel disease (IBD) present a higher risk of developing cardiovascular diseases (CVDs) due to chronic inflammation, which plays an essential role in atherogenesis. Hyperlipidemia is another risk factor for CVDs; however, the association between IBD, IBD medications, and hyperlipidemia remains controversial. We conducted a nationwide, population-based, retrospective, cohort study to examine the effect of IBD and IBD medications on the risk of developing hyperlipidemia. The effects of IBD medications on the expression of lipogenesis-related hepatic genes were also evaluated. We obtained data from the Longitudinal Health Insurance Database of Taiwan from patients with new-onset IBD and a comparison cohort of patients without IBD. A Cox proportional hazards regression model was used to analyze the difference in the risk of developing hyperlipidemia between the two cohorts. We also examined the influence of IBD medications on the expression of lipogenesis-related hepatic genes. After adjusting for comorbidities and confounding factors, the case group (
N
= 14,524) had a higher risk for hyperlipidemia than the control group (
N
= 14,524) [adjusted hazards ratio (aHR), 2.18]. Patients with IBD that did not receive IBD medications exhibited a significantly higher risk of hyperlipidemia (aHR, 2.20). In those treated with IBD medications, the risk of developing hyperlipidemia was significantly lowered than those without such medications (all aHR ≤ 0.45). Gene expression analysis indicated that IBD medications downregulated the expression of lipogenesis-related genes. Screening blood lipids in IBD patients is needed to explore the specific role and impact of IBD medications in the development of CVD. |
|---|---|
| AbstractList | Patients with inflammatory bowel disease (IBD) present a higher risk of developing cardiovascular diseases (CVDs) due to chronic inflammation, which plays an essential role in atherogenesis. Hyperlipidemia is another risk factor for CVDs; however, the association between IBD, IBD medications, and hyperlipidemia remains controversial. We conducted a nationwide, population-based, retrospective, cohort study to examine the effect of IBD and IBD medications on the risk of developing hyperlipidemia. The effects of IBD medications on the expression of lipogenesis-related hepatic genes were also evaluated. We obtained data from the Longitudinal Health Insurance Database of Taiwan from patients with new-onset IBD and a comparison cohort of patients without IBD. A Cox proportional hazards regression model was used to analyze the difference in the risk of developing hyperlipidemia between the two cohorts. We also examined the influence of IBD medications on the expression of lipogenesis-related hepatic genes. After adjusting for comorbidities and confounding factors, the case group (
N
= 14,524) had a higher risk for hyperlipidemia than the control group (
N
= 14,524) [adjusted hazards ratio (aHR), 2.18]. Patients with IBD that did not receive IBD medications exhibited a significantly higher risk of hyperlipidemia (aHR, 2.20). In those treated with IBD medications, the risk of developing hyperlipidemia was significantly lowered than those without such medications (all aHR ≤ 0.45). Gene expression analysis indicated that IBD medications downregulated the expression of lipogenesis-related genes. Screening blood lipids in IBD patients is needed to explore the specific role and impact of IBD medications in the development of CVD. Patients with inflammatory bowel disease (IBD) present a higher risk of developing cardiovascular diseases (CVDs) due to chronic inflammation, which plays an essential role in atherogenesis. Hyperlipidemia is another risk factor for CVDs; however, the association between IBD, IBD medications, and hyperlipidemia remains controversial. We conducted a nationwide, population-based, retrospective, cohort study to examine the effect of IBD and IBD medications on the risk of developing hyperlipidemia. The effects of IBD medications on the expression of lipogenesis-related hepatic genes were also evaluated. We obtained data from the Longitudinal Health Insurance Database of Taiwan from patients with new-onset IBD and a comparison cohort of patients without IBD. A Cox proportional hazards regression model was used to analyze the difference in the risk of developing hyperlipidemia between the two cohorts. We also examined the influence of IBD medications on the expression of lipogenesis-related hepatic genes. After adjusting for comorbidities and confounding factors, the case group (N = 14,524) had a higher risk for hyperlipidemia than the control group (N = 14,524) [adjusted hazards ratio (aHR), 2.18]. Patients with IBD that did not receive IBD medications exhibited a significantly higher risk of hyperlipidemia (aHR, 2.20). In those treated with IBD medications, the risk of developing hyperlipidemia was significantly lowered than those without such medications (all aHR ≤ 0.45). Gene expression analysis indicated that IBD medications downregulated the expression of lipogenesis-related genes. Screening blood lipids in IBD patients is needed to explore the specific role and impact of IBD medications in the development of CVD. Patients with inflammatory bowel disease (IBD) present a higher risk of developing cardiovascular diseases (CVDs) due to chronic inflammation, which plays an essential role in atherogenesis. Hyperlipidemia is another risk factor for CVDs; however, the association between IBD, IBD medications, and hyperlipidemia remains controversial. We conducted a nationwide, population-based, retrospective, cohort study to examine the effect of IBD and IBD medications on the risk of developing hyperlipidemia. The effects of IBD medications on the expression of lipogenesis-related hepatic genes were also evaluated. We obtained data from the Longitudinal Health Insurance Database of Taiwan from patients with new-onset IBD and a comparison cohort of patients without IBD. A Cox proportional hazards regression model was used to analyze the difference in the risk of developing hyperlipidemia between the two cohorts. We also examined the influence of IBD medications on the expression of lipogenesis-related hepatic genes. After adjusting for comorbidities and confounding factors, the case group (N = 14,524) had a higher risk for hyperlipidemia than the control group (N = 14,524) [adjusted hazards ratio (aHR), 2.18]. Patients with IBD that did not receive IBD medications exhibited a significantly higher risk of hyperlipidemia (aHR, 2.20). In those treated with IBD medications, the risk of developing hyperlipidemia was significantly lowered than those without such medications (all aHR ≤ 0.45). Gene expression analysis indicated that IBD medications downregulated the expression of lipogenesis-related genes. Screening blood lipids in IBD patients is needed to explore the specific role and impact of IBD medications in the development of CVD.Patients with inflammatory bowel disease (IBD) present a higher risk of developing cardiovascular diseases (CVDs) due to chronic inflammation, which plays an essential role in atherogenesis. Hyperlipidemia is another risk factor for CVDs; however, the association between IBD, IBD medications, and hyperlipidemia remains controversial. We conducted a nationwide, population-based, retrospective, cohort study to examine the effect of IBD and IBD medications on the risk of developing hyperlipidemia. The effects of IBD medications on the expression of lipogenesis-related hepatic genes were also evaluated. We obtained data from the Longitudinal Health Insurance Database of Taiwan from patients with new-onset IBD and a comparison cohort of patients without IBD. A Cox proportional hazards regression model was used to analyze the difference in the risk of developing hyperlipidemia between the two cohorts. We also examined the influence of IBD medications on the expression of lipogenesis-related hepatic genes. After adjusting for comorbidities and confounding factors, the case group (N = 14,524) had a higher risk for hyperlipidemia than the control group (N = 14,524) [adjusted hazards ratio (aHR), 2.18]. Patients with IBD that did not receive IBD medications exhibited a significantly higher risk of hyperlipidemia (aHR, 2.20). In those treated with IBD medications, the risk of developing hyperlipidemia was significantly lowered than those without such medications (all aHR ≤ 0.45). Gene expression analysis indicated that IBD medications downregulated the expression of lipogenesis-related genes. Screening blood lipids in IBD patients is needed to explore the specific role and impact of IBD medications in the development of CVD. |
| Author | Tien, Ni Wu, Chia-Jui Lin, Cheng-Li Wu, Tien-Yuan Lim, Yun-Ping Fang, Yi-Jen Hsu, Chung-Y |
| AuthorAffiliation | 10 Graduate Institute of Clinical Medicine, Department of Environmental Health, Kaohsiung Medical University , Kaohsiung , Taiwan 1 Department of Laboratory Medicine, China Medical University Hospital , Taichung , Taiwan 13 Department of Internal Medicine, China Medical University Hospital , Taichung , Taiwan 4 Department of Pharmacology, School of Medicine, Tzu Chi University , Hualien , Taiwan 2 Department of Medical Laboratory Science and Biotechnology, China Medical University , Taichung , Taiwan 3 Department of Pharmacy, Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation , Taichung , Taiwan 8 Research Center for Environmental Medicine, Kaohsiung Medical University , Kaohsiung , Taiwan 14 Department of Medical Research, China Medical University Hospital , Taichung , Taiwan 7 Graduate Institute of Biomedical Sciences, China Medical University , Taichung , Taiwan 6 Department of Pharmacy, College of Pharmacy, China Medical University , Taichung , Taiwan 12 Digestive Disease Center, |
| AuthorAffiliation_xml | – name: 13 Department of Internal Medicine, China Medical University Hospital , Taichung , Taiwan – name: 11 National Institute of Environmental Health Sciences, National Health Research Institutes , Zhunan , Taiwan – name: 2 Department of Medical Laboratory Science and Biotechnology, China Medical University , Taichung , Taiwan – name: 6 Department of Pharmacy, College of Pharmacy, China Medical University , Taichung , Taiwan – name: 1 Department of Laboratory Medicine, China Medical University Hospital , Taichung , Taiwan – name: 5 Management Office for Health Data, China Medical University Hospital , Taichung , Taiwan – name: 10 Graduate Institute of Clinical Medicine, Department of Environmental Health, Kaohsiung Medical University , Kaohsiung , Taiwan – name: 9 Ph.D. Program in Environmental and Occupational Medicine, College of Medicine, Kaohsiung Medical University and National Health Research Institutes , Kaohsiung , Taiwan – name: 7 Graduate Institute of Biomedical Sciences, China Medical University , Taichung , Taiwan – name: 4 Department of Pharmacology, School of Medicine, Tzu Chi University , Hualien , Taiwan – name: 14 Department of Medical Research, China Medical University Hospital , Taichung , Taiwan – name: 12 Digestive Disease Center, Show Chwan Memorial Hospital , Changhua , Taiwan – name: 8 Research Center for Environmental Medicine, Kaohsiung Medical University , Kaohsiung , Taiwan – name: 3 Department of Pharmacy, Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation , Taichung , Taiwan |
| Author_xml | – sequence: 1 givenname: Ni surname: Tien fullname: Tien, Ni – sequence: 2 givenname: Tien-Yuan surname: Wu fullname: Wu, Tien-Yuan – sequence: 3 givenname: Cheng-Li surname: Lin fullname: Lin, Cheng-Li – sequence: 4 givenname: Chia-Jui surname: Wu fullname: Wu, Chia-Jui – sequence: 5 givenname: Chung-Y surname: Hsu fullname: Hsu, Chung-Y – sequence: 6 givenname: Yi-Jen surname: Fang fullname: Fang, Yi-Jen – sequence: 7 givenname: Yun-Ping surname: Lim fullname: Lim, Yun-Ping |
| BookMark | eNp1kk1v1DAQhiNUREvpnaOP5ZDFH0nscEDqbks30iJQAYmb5TjjrUtiBztb2H_FT8S7WyGKxMmj8bzPjMfv8-zIeQdZ9pLgGWOifm0G6GYUUzqrCa4oe5KdUFpXuSjF16O_4uPsLMY7jDFhtCwIe5Yds5LzlKhOsl_NMCo9IW9Q40yvhkFNPmzR3P-AHl3aCCoCOm_ml6-Qch1KAXoPndVqst5F5B26sfHbTr_cjhB6O9oOBqv21dahezsFj5YwJoFGKzv6NTir8xvo1QQdugYH6OrnGCDGRHyDLtBHP276PT-fp-4dWvhbHyb0adp02xfZU6P6CGcP52n25d3V58UyX324bhYXq1wXrJ5yxoErTEowBQAQEJwbw4ngreGVbrsOCl1zKHFNdCU04bjgIm2kqCnuGC7YadYcuJ1Xd3IMdlBhK72ycp_wYS1VSE_qQQJTpqU1NroyiSLalrei0AYrUmFessR6e2CNmzZ9mgY3BdU_gj6-cfZWrv29rCkrqMAJcP4ACP77BuIkBxs19L1y4DdR0kpQLkpMSSrFh1IdfIwBzJ82BMudb-TON3LnG3nwTZJU_0i0nfb7T8PY_v_C37ySyrk |
| CitedBy_id | crossref_primary_10_7759_cureus_55268 crossref_primary_10_1007_s00392_025_02605_8 crossref_primary_10_3389_fimmu_2022_1028953 crossref_primary_10_1021_acs_jproteome_4c00623 |
| Cites_doi | 10.1093/ibd/izaa156 10.1016/j.jacl.2010.08.021 10.1097/01.MIB.0000441200.10454.4f 10.1073/pnas.232137699 10.1093/ajcn/71.3.807 10.1136/gut.39.1.63 10.1046/j.1365-2125.2000.00164.x 10.1002/ibd.21187 10.1016/j.tcm.2019.10.001 10.1097/MIB.0000000000000899 10.5217/ir.2017.15.3.266 10.1111/j.1365-2036.2008.03886.x 10.1016/j.clinbiochem.2014.12.018 10.1111/j.1872-034X.2008.00382.x 10.1136/ard.49.8.587 10.1097/MIB.0000000000000531 10.5152/tjg.2021.20293 10.1016/S0929-6441(09)60043-6 10.1111/jgh.12260 10.1136/gut.21.1.49 10.1155/2019/3012509 10.1016/j.ijcard.2016.08.101 10.1053/j.gastro.2014.01.042 10.1016/j.pop.2012.11.003 10.1111/bcpt.13153 10.1371/journal.pone.0254631 10.1155/2015/168905 10.1186/s12876-021-02072-1 10.1016/j.metabol.2006.03.006 10.2174/1573403X16999201210200342 10.2147/CEG.S243478 10.1186/s12986-020-0432-x 10.1053/j.gastro.2011.01.055 10.1016/j.cgh.2019.07.052 10.1097/MED.0000000000000136 10.1016/j.cgh.2013.08.023 10.1111/j.1365-2125.1989.tb05366.x 10.1056/NEJMra020831 10.1101/gad.9.9.1033 10.1016/j.cgh.2019.09.016 10.3390/jcm9051273 10.1007/s10620-015-3932-1 10.1007/s12026-016-8833-7 10.1007/s10620-020-06439-4 10.1038/s41598-021-03407-4 10.1016/j.semarthrit.2021.10.001 10.1093/ibd/izy354 10.1136/gutjnl-2012-303285 10.1007/s00384-008-0503-3 10.5217/ir.2018.00096 10.3390/ijms150711324 10.1101/gad.850400 10.5217/ir.2017.15.3.285 10.1136/gutjnl-2017-314015 10.1038/nrgastro.2014.202 10.2174/1389450116666150202161500 10.1016/j.crohns.2011.01.011 10.2165/00003088-200443120-00003 10.1186/1472-6823-14-91 10.1371/journal.pone.0056944 10.1007/s11605-007-0380-z |
| ContentType | Journal Article |
| Copyright | Copyright © 2022 Tien, Wu, Lin, Wu, Hsu, Fang and Lim. Copyright © 2022 Tien, Wu, Lin, Wu, Hsu, Fang and Lim. 2022 Tien, Wu, Lin, Wu, Hsu, Fang and Lim |
| Copyright_xml | – notice: Copyright © 2022 Tien, Wu, Lin, Wu, Hsu, Fang and Lim. – notice: Copyright © 2022 Tien, Wu, Lin, Wu, Hsu, Fang and Lim. 2022 Tien, Wu, Lin, Wu, Hsu, Fang and Lim |
| DBID | AAYXX CITATION 7X8 5PM DOA |
| DOI | 10.3389/fmed.2022.910623 |
| DatabaseName | CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Open Access Full Text |
| DatabaseTitle | CrossRef MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2296-858X |
| ExternalDocumentID | oai_doaj_org_article_e3afb290fc6f4788bb7b84cf0a160753 PMC9234280 10_3389_fmed_2022_910623 |
| GroupedDBID | 53G 5VS 9T4 AAFWJ AAYXX ACGFS ACXDI ADBBV ADRAZ AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK GROUPED_DOAJ HYE KQ8 M48 M~E OK1 PGMZT RPM 7X8 5PM |
| ID | FETCH-LOGICAL-c439t-37e7a015ef4eee1e877ff7187bf76cbdde4c97e5091c68c1704780064920d3043 |
| IEDL.DBID | M48 |
| ISSN | 2296-858X |
| IngestDate | Wed Aug 27 00:40:35 EDT 2025 Thu Aug 21 18:33:01 EDT 2025 Sun Aug 24 03:54:23 EDT 2025 Thu Apr 24 22:56:52 EDT 2025 Tue Jul 01 04:05:27 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Language | English |
| License | This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c439t-37e7a015ef4eee1e877ff7187bf76cbdde4c97e5091c68c1704780064920d3043 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Reviewed by: Kevin Sheng-Kai Ma, University of Pennsylvania, United States; Chung-Han Ho, Chi Mei Medical Center, Taiwan This article was submitted to Family Medicine and Primary Care, a section of the journal Frontiers in Medicine Edited by: Antonietta G. Gravina, University of Campania Luigi Vanvitelli, Italy These authors have contributed equally to this work |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fmed.2022.910623 |
| PMID | 35770006 |
| PQID | 2682785021 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_e3afb290fc6f4788bb7b84cf0a160753 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9234280 proquest_miscellaneous_2682785021 crossref_primary_10_3389_fmed_2022_910623 crossref_citationtrail_10_3389_fmed_2022_910623 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-06-13 |
| PublicationDateYYYYMMDD | 2022-06-13 |
| PublicationDate_xml | – month: 06 year: 2022 text: 2022-06-13 day: 13 |
| PublicationDecade | 2020 |
| PublicationTitle | Frontiers in medicine |
| PublicationYear | 2022 |
| Publisher | Frontiers Media S.A |
| Publisher_xml | – name: Frontiers Media S.A |
| References | Kumar (B2) 2021; 66 Cosnes (B7) 2011; 140 Rungoe (B14) 2013; 62 Singh (B25) 2015; 12 Zuin (B66) 2016; 222 Steyers (B61) 2014; 15 Bigeh (B57) 2020; 30 Loftus (B6) 2016; 12 Rabinowich (B62) 2015; 2015 Wei (B3) 2017; 15 Bollen (B10) 2015; 21 Hussain (B46) 2000; 49 Panhwar (B18) 2019; 25 Saiz-Rodríguez (B43) 2019; 124 Kristensen (B13) 2013; 8 Lazzerini (B64) 2017; 65 Gripon (B68) 2002; 99 Lemaitre (B42) 2015; 48 Podolsky (B27) 2002; 347 Willy (B31) 1995; 9 Changchien (B29) 2003; 11 Tan (B9) 2013; 28 Romanato (B52) 2009; 29 Wei (B4) 2017; 15 Wang (B30) 2021; 21 Higuchi (B33) 2008; 38 Tsai (B16) 2014; 20 Barnes (B65) 2016; 22 B41 Liu (B34) 2020; 17 B45 Elliott (B36) 1980; 21 Scarpa (B49) 2008; 12 Kirchgesner (B17) 2018; 67 Astbury (B44) 1990; 49 Schicho (B8) 2015; 16 Levy (B23) 2000; 71 Card (B19) 2021; 27 Sappati Biyyani (B22) 2010; 4 Van Os (B39) 1996; 39 Lu (B67) 2021; 32 Yeshi (B28) 2020; 9 Hoekstra (B40) 2004; 31 Alloubani (B54) 2021; 17 Schultz (B32) 2000; 14 Ripollés Piquer (B24) 2006; 55 Lai (B47) 2020; 18 Groenendyk (B58) 2021; 11 Becker (B51) 1996; 91 Sridhar (B12) 2011; 5 Bunu (B26) 2019; 2019 Al-Habet (B37) 1989; 27 He (B63) 2021; 51 Jess (B1) 2020; 18 Yen (B5) 2019; 17 Kohan (B60) 2015; 22 Tigas (B59) 2012; 25 Singh (B11) 2014; 12 Romanato (B48) 2008; 23 Biondi (B53) 2020; 13 Agouridis (B50) 2011; 24 Nelson (B20) 2013; 40 Jung (B38) 2014; 14 Koutroumpakis (B21) 2016; 61 Edsbäcker (B35) 2004; 43 Ferrara (B55) 2021; 16 Nguyen (B15) 2014; 146 Andersohn (B56) 2010; 16 |
| References_xml | – volume: 27 start-page: 629 year: 2021 ident: B19 article-title: Disease activity in inflammatory bowel disease is associated with arterial vascular disease publication-title: Inflamm Bowel Dis. doi: 10.1093/ibd/izaa156 – volume: 4 start-page: 478 year: 2010 ident: B22 article-title: Dyslipidemia and lipoprotein profiles in patients with inflammatory bowel disease publication-title: J Clin Lipidol. doi: 10.1016/j.jacl.2010.08.021 – volume: 20 start-page: 502 year: 2014 ident: B16 article-title: Long-term risk of acute coronary syndrome in patients with inflammatory bowel disease: a 13-year nationwide cohort study in an Asian population publication-title: Inflamm Bowel Dis. doi: 10.1097/01.MIB.0000441200.10454.4f – volume: 99 start-page: 15655 year: 2002 ident: B68 article-title: Infection of a human hepatoma cell line by hepatitis B virus publication-title: Proc Natl Acad Sci U S A. doi: 10.1073/pnas.232137699 – volume: 71 start-page: 807 year: 2000 ident: B23 article-title: Altered lipid profile, lipoprotein composition, and oxidant and antioxidant status in pediatric Crohn disease publication-title: Am J Clin Nutr. doi: 10.1093/ajcn/71.3.807 – volume: 39 start-page: 63 year: 1996 ident: B39 article-title: Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration publication-title: Gut. doi: 10.1136/gut.39.1.63 – volume: 49 start-page: 323 year: 2000 ident: B46 article-title: Dose loading with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters publication-title: Br J Clin Pharmacol. doi: 10.1046/j.1365-2125.2000.00164.x – volume: 16 start-page: 1387 year: 2010 ident: B56 article-title: Risk of ischemic stroke in patients with Crohn's disease: a population-based nested case-control study publication-title: Inflamm Bowel Dis. doi: 10.1002/ibd.21187 – volume: 30 start-page: 463 year: 2020 ident: B57 article-title: Inflammatory bowel disease and the risk for cardiovascular disease: does all inflammation lead to heart disease? publication-title: Trends Cardiovasc Med. doi: 10.1016/j.tcm.2019.10.001 – volume: 22 start-page: 2229 year: 2016 ident: B65 article-title: Hospitalizations for acute myocardial infarction are decreased among patients with inflammatory bowel disease using a nationwide inpatient database publication-title: Inflamm Bowel Dis. doi: 10.1097/MIB.0000000000000899 – volume: 15 start-page: 266 year: 2017 ident: B3 article-title: Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan society of inflammatory bowel disease publication-title: Intest Res. doi: 10.5217/ir.2017.15.3.266 – ident: B41 – volume: 29 start-page: 298 year: 2009 ident: B52 article-title: Plasma lipids and inflammation in active inflammatory bowel diseases publication-title: Aliment Pharmacol Ther. doi: 10.1111/j.1365-2036.2008.03886.x – ident: B45 – volume: 48 start-page: 406 year: 2015 ident: B42 article-title: Pharmacokinetics and pharmacodynamics of tacrolimus in liver transplant recipients: inside the white blood cells publication-title: Clin Biochem. doi: 10.1016/j.clinbiochem.2014.12.018 – volume: 38 start-page: 1122 year: 2008 ident: B33 article-title: Liver X receptor in cooperation with SREBP-1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease publication-title: Hepatol Res. doi: 10.1111/j.1872-034X.2008.00382.x – volume: 49 start-page: 587 year: 1990 ident: B44 article-title: Comparison of the single dose pharmacokinetics of sulphasalazine in rheumatoid arthritis and inflammatory bowel disease publication-title: Ann Rheum Dis. doi: 10.1136/ard.49.8.587 – volume: 21 start-page: 2540 year: 2015 ident: B10 article-title: The occurrence of thrombosis in inflammatory bowel disease is reflected in the clot lysis profile publication-title: Inflamm Bowel Dis. doi: 10.1097/MIB.0000000000000531 – volume: 32 start-page: 422 year: 2021 ident: B67 article-title: Arterial stiffness in inflammatory bowel disease: an updated systematic review and meta-analysis publication-title: Turk J Gastroenterol. doi: 10.5152/tjg.2021.20293 – volume: 11 start-page: 60 year: 2003 ident: B29 article-title: Correlation between fatty liver and lipidemia in Taiwanese publication-title: J Med Ultrasound. doi: 10.1016/S0929-6441(09)60043-6 – volume: 28 start-page: 1095 year: 2013 ident: B9 article-title: Venous and arterial disease in inflammatory bowel disease publication-title: J Gastroenterol Hepatol. doi: 10.1111/jgh.12260 – volume: 21 start-page: 49 year: 1980 ident: B36 article-title: Prednisolone absorption in acute colitis publication-title: Gut. doi: 10.1136/gut.21.1.49 – volume: 2019 start-page: 3012509 year: 2019 ident: B26 article-title: Cardiovascular manifestations of inflammatory bowel disease: Pathogenesis, diagnosis, and preventive strategies publication-title: Gastroenterol Res Pract Actions. doi: 10.1155/2019/3012509 – volume: 222 start-page: 984 year: 2016 ident: B66 article-title: Cardiovascular disease in patients with inflammatory bowel disease: an issue in no guidelines land publication-title: Int J Cardiol. doi: 10.1016/j.ijcard.2016.08.101 – volume: 146 start-page: 835 year: 2014 ident: B15 article-title: Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology publication-title: Gastroenterology. doi: 10.1053/j.gastro.2014.01.042 – volume: 40 start-page: 195 year: 2013 ident: B20 article-title: Hyperlipidemia as a risk factor for cardiovascular disease publication-title: Prim Care. doi: 10.1016/j.pop.2012.11.003 – volume: 91 start-page: 2452 year: 1996 ident: B51 article-title: Lipid profiles in Crohn's disease patients with and without ileal resection publication-title: Am J Gastroenterol. – volume: 124 start-page: 449 year: 2019 ident: B43 article-title: Influence of thiopurine S-methyltransferase polymorphisms in mercaptopurine pharmacokinetics in healthy volunteers publication-title: Basic Clin Pharmacol Toxicol. doi: 10.1111/bcpt.13153 – volume: 16 start-page: e0254631 year: 2021 ident: B55 article-title: The economic impact of hypercholesterolemia and mixed dyslipidemia: a systematic review of cost of illness studies publication-title: PLoS One. doi: 10.1371/journal.pone.0254631 – volume: 2015 start-page: 168905 year: 2015 ident: B62 article-title: Drug induced steatohepatitis: An uncommon culprit of a common disease publication-title: Biomed Res Int. doi: 10.1155/2015/168905 – volume: 21 start-page: 482 year: 2021 ident: B30 article-title: Comparison of several blood lipid-related indexes in the screening of non-alcoholic fatty liver disease in women: a cross-sectional study in the Pearl River Delta region of southern China publication-title: BMC Gastroenterol. doi: 10.1186/s12876-021-02072-1 – volume: 55 start-page: 980 year: 2006 ident: B24 article-title: Altered lipid, apolipoprotein, and lipoprotein profiles in inflammatory bowel disease: consequences on the cholesterol efflux capacity of serum using Fu5AH cell system publication-title: Metabolism. doi: 10.1016/j.metabol.2006.03.006 – volume: 17 start-page: e051121189015 year: 2021 ident: B54 article-title: Relationship between hyperlipidemia, cardiovascular disease and stroke: a systematic review publication-title: Curr Cardiol Rev. doi: 10.2174/1573403X16999201210200342 – volume: 13 start-page: 107 year: 2020 ident: B53 article-title: Cardiovascular risk in individuals with inflammatory bowel disease publication-title: Clin Exp Gastroenterol. doi: 10.2147/CEG.S243478 – volume: 25 start-page: 37 year: 2012 ident: B59 article-title: Endocrine and metabolic manifestations in inflammatory bowel disease publication-title: Ann Gastroenterol. – volume: 17 start-page: 12 year: 2020 ident: B34 article-title: Tetramethylpyrazine reverses high-glucose induced hypoxic effects by negatively regulating HIF-1α induced BNIP3 expression to ameliorate H9c2 cardiomyoblast apoptosis publication-title: Nutr Metab. doi: 10.1186/s12986-020-0432-x – volume: 140 start-page: 1785 year: 2011 ident: B7 article-title: Epidemiology and natural history of inflammatory bowel diseases publication-title: Gastroenterology. doi: 10.1053/j.gastro.2011.01.055 – volume: 18 start-page: 881 year: 2020 ident: B1 article-title: Inflammatory bowel diseases increase risk of type 2 diabetes in a nationwide cohort study publication-title: Clin Gastroenterol Hepatol. doi: 10.1016/j.cgh.2019.07.052 – volume: 22 start-page: 119 year: 2015 ident: B60 article-title: Apolipoprotein C-III: a potent modulator of hypertriglyceridemia and cardiovascular disease publication-title: Curr Opin Endocrinol Diabetes Obes. doi: 10.1097/MED.0000000000000136 – volume: 12 start-page: 382 year: 2014 ident: B11 article-title: Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: a systematic review and meta-analysis publication-title: Clin Gastroenterol Hepatol. doi: 10.1016/j.cgh.2013.08.023 – volume: 27 start-page: 285 year: 1989 ident: B37 article-title: Methylprednisolone pharmacokinetics after intravenous and oral administration publication-title: Br J Clin Pharmacol. doi: 10.1111/j.1365-2125.1989.tb05366.x – volume: 347 start-page: 417 year: 2002 ident: B27 article-title: Inflammatory bowel disease publication-title: N Engl J Med. doi: 10.1056/NEJMra020831 – volume: 9 start-page: 1033 year: 1995 ident: B31 article-title: a nuclear receptor that defines a distinct retinoid response pathway publication-title: Genes Dev. doi: 10.1101/gad.9.9.1033 – volume: 18 start-page: 1002 year: 2020 ident: B47 article-title: Association between inflammatory bowel disease and diabetes mellitus publication-title: Clin Gastro Hepatol. doi: 10.1016/j.cgh.2019.09.016 – volume: 9 start-page: 1273 year: 2020 ident: B28 article-title: Revisiting inflammatory bowel disease: Pathology, treatments, challenges and emerging therapeutics including drug leads from natural products publication-title: J Clin Med. doi: 10.3390/jcm9051273 – volume: 61 start-page: 865 year: 2016 ident: B21 article-title: Association between long-term lipid profiles and disease severity in a large cohort of patients with inflammatory bowel disease publication-title: Dig Dis Sci. doi: 10.1007/s10620-015-3932-1 – volume: 65 start-page: 262 year: 2017 ident: B64 article-title: Biologic drugs and arrhythmic risk in chronic inflammatory arthritis: the good and the bad publication-title: Immunol Res. doi: 10.1007/s12026-016-8833-7 – volume: 66 start-page: 2005 year: 2021 ident: B2 article-title: Comorbid diabetes in inflammatory bowel disease predicts adverse disease-related outcomes and infectious complications publication-title: Dig Dis Sci. doi: 10.1007/s10620-020-06439-4 – volume: 11 start-page: 23985 year: 2021 ident: B58 article-title: Changes in proportionate cardiovascular mortality in patients with chronic infectious and inflammatory conditions in the United States, 1999-2018 publication-title: Sci Rep. doi: 10.1038/s41598-021-03407-4 – volume: 51 start-page: 1242 year: 2021 ident: B63 article-title: Risk of venous thromboembolism associated with methotrexate versus hydroxychloroquine for rheumatoid arthritis: A propensity score-matched cohort study publication-title: Semin Arthritis Rheum. doi: 10.1016/j.semarthrit.2021.10.001 – volume: 25 start-page: 1080 year: 2019 ident: B18 article-title: Risk of myocardial infarction in inflammatory bowel disease: a population-based national study publication-title: Inflamm Bowel Dis. doi: 10.1093/ibd/izy354 – volume: 62 start-page: 689 year: 2013 ident: B14 article-title: Risk of ischaemic heart disease in patients with inflammatory bowel disease: a nationwide Danish cohort study publication-title: Gut. doi: 10.1136/gutjnl-2012-303285 – volume: 31 start-page: 645 year: 2004 ident: B40 article-title: Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis publication-title: J Rheumatol. – volume: 23 start-page: 931 year: 2008 ident: B48 article-title: Lipid and phospholipid profile after bowel resection for Crohn's disease publication-title: Int J Colorectal Dis. doi: 10.1007/s00384-008-0503-3 – volume: 24 start-page: 181 year: 2011 ident: B50 article-title: An overview of lipid abnormalities in patients with inflammatory bowel disease publication-title: Ann Gastroenterol. – volume: 17 start-page: 54 year: 2019 ident: B5 article-title: Epidemiological trend in inflammatory bowel disease in Taiwan from 2001 to 2015: a nationwide population-based study publication-title: Intest Res. doi: 10.5217/ir.2018.00096 – volume: 15 start-page: 11324 year: 2014 ident: B61 article-title: Endothelial dysfunction in chronic inflammatory diseases publication-title: Int J Mol Sci. doi: 10.3390/ijms150711324 – volume: 14 start-page: 2831 year: 2000 ident: B32 article-title: Role of LXRs in control of lipogenesis publication-title: Genes Dev. doi: 10.1101/gad.850400 – volume: 15 start-page: 285 year: 2017 ident: B4 article-title: Management of Crohn's disease in Taiwan: consensus guideline of the Taiwan society of inflammatory bowel disease publication-title: Intest Res. doi: 10.5217/ir.2017.15.3.285 – volume: 67 start-page: 1261 year: 2018 ident: B17 article-title: BERENICE study group. Increased risk of acute arterial events in young patients and severely active IBD: a nationwide French cohort study publication-title: Gut. doi: 10.1136/gutjnl-2017-314015 – volume: 12 start-page: 26 year: 2015 ident: B25 article-title: Epidemiology, risk factors and management of cardiovascular diseases in IBD publication-title: Nat Rev Gastroenterol Hepatol. doi: 10.1038/nrgastro.2014.202 – volume: 16 start-page: 181 year: 2015 ident: B8 article-title: Cardiovascular complications in inflammatory bowel disease publication-title: Curr Drug Targets. doi: 10.2174/1389450116666150202161500 – volume: 5 start-page: 287 year: 2011 ident: B12 article-title: Comprehensive study of cardiovascular morbidity in hospitalized inflammatory bowel disease patients publication-title: J Crohns Colitis. doi: 10.1016/j.crohns.2011.01.011 – volume: 43 start-page: 803 year: 2004 ident: B35 article-title: Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease publication-title: Clin Pharmacokinet. doi: 10.2165/00003088-200443120-00003 – volume: 14 start-page: 91 year: 2014 ident: B38 article-title: Plasma, salivary and urinary cortisol levels following physiological and stress doses of hydrocortisone in normal volunteers publication-title: BMC Endocr Disord. doi: 10.1186/1472-6823-14-91 – volume: 8 start-page: e56944 year: 2013 ident: B13 article-title: Disease activity in inflammatory bowel disease is associated with increased risk of myocardial infarction, stroke and cardiovascular death: a Danish nationwide cohort study publication-title: PLoS ONE. doi: 10.1371/journal.pone.0056944 – volume: 12 start-page: 704 year: 2016 ident: B6 article-title: Update on the incidence and prevalence of inflammatory bowel disease in the United States publication-title: Gastroenterol Hepatol. – volume: 12 start-page: 279 year: 2008 ident: B49 article-title: Restorative proctocolectomy for ulcerative colitis: impact on lipid metabolism and adipose tissue and serum fatty acids publication-title: J Gastrointest Surg. doi: 10.1007/s11605-007-0380-z |
| SSID | ssj0001325413 |
| Score | 2.22129 |
| Snippet | Patients with inflammatory bowel disease (IBD) present a higher risk of developing cardiovascular diseases (CVDs) due to chronic inflammation, which plays an... |
| SourceID | doaj pubmedcentral proquest crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Enrichment Source Index Database |
| StartPage | 910623 |
| SubjectTerms | hyperlipidemia IBD medications inflammatory bowel disease (IBD) lipogenesis Longitudinal Health Insurance Database (LHID) Medicine |
| SummonAdditionalLinks | – databaseName: DOAJ Open Access Full Text dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gL4ikWKBokDvQQmjheO-HW7UO7iCKEqNRbFDtjNWJxqu2Wwr_iJzLjpKvNBS7cosSWnczY801m_I0Qb2TWyFpjnnhbenJQvE2sxiJRTpfS5QSaFR9wPv2k52fqw_n0fKvUF-eE9fTA_Yfbx7z2Vpapd9oz1bu1xhbK-bRmarRp5Pkkm7flTMW_Kzk5PlnexyXJCytJTMjEoFK-IwOpZT6yQ5Guf4QxxxmSWybn5IG4P2BFOOjn-FDcwfBI3D0douGPxe9FPOIInYdF8CTa7zFkDrPuBpdw1Ide4O1idrQHdWiALqAPzERlgy7Al_bqG_efkzu6WrZ9udg6tm4D_GjXqw7myFnXDj62lx2pW-uSmEGHDTBnNRz_HHJpw3s4gM-bgmDJjEZv4LC7IIQPnK_464k4Ozn-ejhPhgoMiSOgsqbdB01NgAG9QsQMC2O8J2tmrDfaWdoalSsNMuhwunCZYa4fRjmlTJs8VflTsRO6gM8EWDf1Te0MuqxUtXFWNTK1vtFeM2UZTsT-rTwqN9CTc5WMZUVuCkuwYglWLMGql-BE7G16XPbUHH9pO2MRb9oxqXa8QapWDapW_UvVJuL1rYJUtAg5slIH7K6vKqkLaYop4aWJMCPNGY04fhLai0jnTRCbfMD0-f-Y4gtxj9-ac9my_KXYWa-ucZdQ09q-igvkDwApGUU priority: 102 providerName: Directory of Open Access Journals |
| Title | Impact of Inflammatory Bowel Disease (IBD) and IBD Medications on Risk of Hyperlipidemia and in vitro Hepatic Lipogenic-Related Gene Expression: A Population-Based Cohort Study |
| URI | https://www.proquest.com/docview/2682785021 https://pubmed.ncbi.nlm.nih.gov/PMC9234280 https://doaj.org/article/e3afb290fc6f4788bb7b84cf0a160753 |
| Volume | 9 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELagSIgL4imWRzVIHOghJXGydoKEULcP7SIWIcRKvUWxM6YRS1KyW2j_FT-RGSddiFRx4hYldl6fnfkmM_5GiBcyKmWhMA6cyRw5KM4ERmEaJFZl0sZEmhNe4Dz_oKaL5N3x-PjP8uj-Ba6udO24ntSiXe6ef794SxP-DXucZG8JAWTNTyl3yfaROb8ubpBd0lzPYN6Tff_HJSZnKIq7WOWVHQe2yUv4D3jnMGvyLzN0dEfc7vkj7HWA3xXXsL4nbs77CPl98Wvmlz1C42BWO4L7mw-jw6T5iUs46MIx8HI2OdiBoi6BNqAL1vgBCE0Nn6rVV-4_JRe1XVZdCdnCt65q-FGt2wamyJnYFt5Xpw0NwcoGPqsOS2Adazg87_Nr69ewBx83RcKCCV29hP3mhF44cA7jxQOxODr8vD8N-qoMgSXysqYvEuqCSAS6BBEjTLV2jiycNk4ra-hzmdhMIxMRq1Ibadb_YeaTybCMwyR-KLbqpsZHAowdu7KwGm2UJYW2JillaFypnGIZMxyJV5d45LaXLOfKGcucXBdGMGcEc0Yw7xAciZ1Nj9NOruMfbScM8aYdC237HU37Je_nbY5x4YzMQmeV40oDxmiTJtaFBSvzjekkzy8HSE4Tk6MtRY3N2SqXKpU6HROHGgk9GDmDKw6P1NWJl_gm2k1-Yfj4f9ziE3GLn5rz26L4qdhat2f4jJjU2mz7PxDbfpr8BoVsIdk |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Impact+of+Inflammatory+Bowel+Disease+%28IBD%29+and+IBD+Medications+on+Risk+of+Hyperlipidemia+and+in+vitro+Hepatic+Lipogenic-Related+Gene+Expression%3A+A+Population-Based+Cohort+Study&rft.jtitle=Frontiers+in+medicine&rft.au=Ni+Tien&rft.au=Ni+Tien&rft.au=Tien-Yuan+Wu&rft.au=Tien-Yuan+Wu&rft.date=2022-06-13&rft.pub=Frontiers+Media+S.A&rft.eissn=2296-858X&rft.volume=9&rft_id=info:doi/10.3389%2Ffmed.2022.910623&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_e3afb290fc6f4788bb7b84cf0a160753 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2296-858X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2296-858X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2296-858X&client=summon |